Malgorzata Beryt

Medicine · Health Sciences

9h-index1.7kcitations15works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(10), Monoclonal and Polyclonal Antibodies Research(9), Cancer Treatment and Pharmacology(3), Glycosylation and Glycoproteins Research(2), Colorectal Cancer Treatments and Studies(2)

Publications15 total

Rational Optimization of a Bispecific Ligand Trap Targeting EGF Receptor Family Ligands
Molecular Medicine·2009· 14 citedOpen Access
Hermodulins: bispecific ligand traps inhibit breast tumor growth and metastasis.
Cancer Research·2009
Human epidermal growth factor receptor (HER-1:HER-3) Fc-mediated heterodimer has broad antiproliferative activity<i>in vitro</i>and in human tumor xenografts
Molecular Cancer Therapeutics·2008· 34 cited
315 POSTER A novel pan-HER ligand trap based on human EGFR (HER1) and HER3 inhibits tumor growth and metastasis in models of human cancer
European Journal of Cancer Supplements·2008
HER family ligand traps (Hermodulins) inhibit tumor cell proliferation in vitro and growth of subcutaneous tumors in nude mice
Clinical Cancer Research·2008
Evaluation of ligand binding and preclinical pharmacokinetics of Hermodulins: A new class of bi-specific protein antagonists that trap most growth factors for the human EGF receptor (HER) family
Cancer Research·2008
HER family ligand traps (Hermodulins) inhibit tumor cell proliferation in vitro and growth of subcutaneous tumors in nude mice
Cancer Research·2008
Predicting chemotherapy response to paclitaxel with 18F-Fluoropaclitaxel and PET.
PubMed·2006· 40 cited
Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel.
PubMed·2005· 100 cited
Characterization of HER2 overexpressing breast cell lines selected for long-term culture with trastuzumab
Cancer Research·2005· 3 cited
Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer
JNCI Journal of the National Cancer Institute·2004· 509 cited
Association between HER-2/<b> <i>neu</i> </b> and Vascular Endothelial Growth Factor Expression Predicts Clinical Outcome in Primary Breast Cancer Patients
Clinical Cancer Research·2004· 311 citedOpen Access
Quantitative Association Between HER-2/neu and Steroid Hormone Receptors in Hormone Receptor-Positive Primary Breast Cancer
JNCI Journal of the National Cancer Institute·2003· 589 citedOpen Access
Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples
Breast Cancer Research and Treatment·2001· 34 cited
Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase11Abbreviations: BVdU, (E)-5-(2-bromovinyl)-2′-deoxyuridine; BVdUMP, (E)-5-(2-bromovinyl)-2′-deoxyuridine 5′-monophosphate; NB1011, (E)-5-(2-bromovinyl)-2′-deoxy-5′-uridyl phenyl l-methoxyalaninylphosphoramidate; COSY, correlated spectroscopy; DCI, direct current ionization; DMF, N,N-dimethylformamide; dUMP, 2′-deoxyuridine 5′-monophosphate; ECTA, enzyme-catalyzed therapeutic agent; 5-FU, 5-fluorouracil; 5-FdUMP, 5-fluoro-2′-deoxyuridine 5′-monophosphate; RFU, relative fluorescence units; THF, N5,N10-methylene tetrahydrofolate; TBDMS, tert-butyldimethylsilyl; and TS, thymidylate synthase (EC 2.1.1.45).
Biochemical Pharmacology·2001· 38 cited

Frequent Co-authors

Mark D. Pegram(8), Dennis J. Slamon(5), Cathleen Brdlik(5), H. Michael Shepard(5), Jin Pei(4), Lisa Turin(4), Xiaomei Bai(4), Jeffrey N. Higaki(4), Brett Jorgensen(4), Daniel C. Maneval(4), Gottfried E. Konecny(3), Michael Untch(3), H. Hepp(3), H. Michael Shepard(3), Peter F. Lindley(3), Jim Liu(3), Juan Zhang(3), Ingo Bauerfeind(2), Anne Gangloff(2), Wei‐Ann Hsueh(2)